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There is great interest in drug discovery programs targeted at the aggregation of the 42-
residue form of the amyloid β peptide (Aβ42), since this molecular process is closely
associated with Alzheimer’s disease. The use of bicyclic peptides may offer novel
opportunities for the effective modification of Aβ42 aggregation and the inhibition of its
cytotoxicity, as these compounds combine the molecular recognition ability of antibodies
with a relatively small size of about 2 kD. Here, to pursue this approach, we rationally
designed a panel of six bicyclic peptides targeting various epitopes along the sequence
of Aβ42 to scan its most amyloidogenic region (residues 13–42). Our kinetic analysis
and structural studies revealed that at sub-stoichiometric concentrations the designed
bicyclic peptides induce a delay in the condensation of Aβ42 and the subsequent
transition to a fibrillar state, while at higher concentrations they inhibit such transition.
We thus suggest that designed bicyclic peptides can be employed to inhibit amyloid
formation by redirecting the aggregation process toward amorphous assemblies.
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INTRODUCTION
Since the formation of aberrant deposits composed primarily of the Aβ peptide is a molecular
hallmark of Alzheimer’s disease (Selkoe and Hardy, 2016; Jack et al., 2018), a major therapeutic
strategy for this condition has been based on the discovery of compounds capable of inhibiting Aβ
aggregation (Schenk et al., 1999; Sevigny et al., 2016). However, disease-modifying compounds have
not yet become available (Cummings et al., 2020). Major drug discovery efforts have been devoted
to the identification of small molecules, which have high brain penetration and low manufacturing
costs, but also typically low specificity and high risk of side effects. In parallel, other efforts have
been devoted to the development of antibodies, which have the advantage of high specificity, but
the disadvantages of high manufacturing costs, difficulty for administration, low permeability, and
sometimes poor developability (Sormanni et al., 2018).
Bicyclic peptides have recently been introduced in the drug discovery field as they are thought to
enable the combination of the advantages of small molecules with those of antibodies (Driggers
et al., 2008; Getz et al., 2011; Angelini et al., 2012; Lian et al., 2014; Quartararo et al., 2014;
Bartoloni et al., 2015; Bionda and Fasan, 2015). These molecules consist of polypeptide chains
where three cysteine residues spaced within the sequence are chemically linked to a cyclic
Frontiers in Neuroscience | www.frontiersin.org 1 February 2021 | Volume 15 | Article 623097
fnins-15-623097 February 19, 2021 Time: 19:3 # 2
Ikenoue et al. Rationally Designed Bicyclic Peptides
compound. This design results in the formation of two
macrocyclic rings that serve as binding regions (Figure 1). As the
topology of bicyclic peptides is restrained, they have a relatively
small entropy cost upon binding and thus a good binding affinity
and specificity (Angelini et al., 2012; Chen et al., 2014; Bionda
and Fasan, 2015). Having a small size of about 2 kDa, at least
in principle, they are endowed with multiple advantages over
antibodies, including the possibility of simple chemical synthesis,
better tissue penetration, higher resistance to protease cleavage
and inactivation, and extended half-life in vivo (Bock et al., 2013).
Bicyclic peptides against specific targets can be developed in a
variety of ways. Phage display, for example, can be used for the
isolation of these compounds from large combinatorial libraries
(Heinis et al., 2009; Angelini et al., 2012; Baeriswyl and Heinis,
2013). This method, however, may become time-consuming and
at times ineffective, in particular when one aims at targeting
aggregation-prone antigens or weakly immunogenic epitopes.
To overcome these limitations, we have introduced a method
for the rationally design of antibodies (Aprile et al., 2015, 2017;
Sormanni et al., 2015a, 2018) and bicyclic peptides (Ikenoue et al.,
2020), which enables the targeting of specific epitopes within
intrinsically disordered proteins.
Here, we present an application of this design strategy by
generating a panel of bicyclic peptides capable of binding Aβ42
and interfering with its aggregation process. Aβ42 aggregates
through a complex process that involves the combination
of different microscopic steps and multiple molecular species
(Cohen et al., 2013; Michaels et al., 2018). In this context, it
is becoming increasingly recognized that the Aβ42 oligomers
formed during the aggregation process are highly neurotoxic
(Benilova et al., 2012; Mannini et al., 2014). Therefore,
therapeutic strategies are being developed to decrease the
concentrations of these oligomeric species, for example, by
delaying or preventing their formation (Bucciantini et al., 2002;
Kayed et al., 2003; Lesne et al., 2006; Haass and Selkoe, 2007;
Benilova et al., 2012; Cremades et al., 2012; Cohen et al., 2013;
Aprile et al., 2017). In one of such strategies, the amyloid
aggregation process is redirected toward off-pathway non-toxic
species. The small molecule trodusquemine, for example, can
modulate the aggregation process of Aβ42 and by redirecting
it toward the formation of off-pathway non-toxic aggregates
(Limbocker et al., 2019). Furthermore, strategies aimed at
reducing the populations of oligomers by speeding up the
aggregation process have also been proposed (Bieschke et al.,
2011; Civitelli et al., 2016; Sonzini et al., 2017). Along these
lines, we show here that our rationally designed bicyclic peptides
prevent the conversion of Aβ42 assemblies into fibrillar structure.
RESULTS
Rational Design and Synthesis of
Bicyclic Peptides Targeting Different
Aβ42 Epitopes
We employed the cascade method, a computational
antibody discovery strategy (Sormanni et al., 2015a, 2018;
Ikenoue et al., 2020), to generate six bicyclic peptides targeting
different regions of the amino acid sequence of Aβ42 (section
“Materials and Methods”). These six peptides (DesBP1–DesBP6)
were designed to scan epitopes in the most amyloidogenic region
of Aβ42 (residues 13–42) (Figure 1A) (section “Materials and
Methods”). For the cyclization, we incorporated in the designed
sequences three cysteine residues separated by two groups of
six residues (Figure 1A). Because the cyclization achieved via
reducible disulfide bonds could be problematic for therapeutic
purposes, we then used tris-(bromomethyl)benzene (TBMB),
a small bromine-containing organic compound, as a scaffold
to anchor each designed peptide (Figure 1B). We carried
out the reaction in aqueous solvents at 30◦C in 1 h, with the
threefold rotational symmetry of the TBMB molecule ensuring
the formation of a unique structural and spatial isomer. The
synthesized bicyclic peptides showed high purity. To assess
the solubility of the DesBPs in phosphate buffer, static and
dynamic light scattering (DLS) measurements were performed
immediately after ultracentrifugation (Supplementary Figures
S1a,b). The results showed 50 µM of all the DesBPs remained
largely soluble at 5◦C, except DesBP4, which formed assemblies
of about ∼140 nm in size (Supplementary Figure S1d). Far-UV
CD spectra show that DesBP1, DesBP2, DesBP5, and DesBP6
tend to retain structured states (Supplementary Figure S1c).
AFM images taken after 1 day, however, showed the presence of
assemblies in all cases (Supplementary Figure S1d).
Characterization of the Effects of the
DesBPs on the Aggregation Kinetics of
Aβ42
In order to investigate the effects of the DesBPs on Aβ42
aggregation, we carried out in vitro aggregation assays using the
fluorescent dye thioflavin T (ThT) as amyloid-sensitive probe. We
monitored Aβ42 fibril formation at the concentration of 2 µM
in the presence of different molar ratios [Aβ42]:[DesBP] (from
0.05 to 16) at 37◦C under quiescent conditions, using a highly
reproducible aggregation assay previously described (Hellstrand
et al., 2010; Ikenoue et al., 2020).
Sub-Stoichiometric Concentrations of DesBPs Delay
Aβ42 Aggregation and Increase ThT Fluorescence
In the presence of low concentrations of DesBPs, we observed
significant changes in the ThT fluorescence intensities in the
presence of DesBP1, DesBP2, DesBP5, and DesBP6, both in
unseeded (Figures 2A–C) and in seeded assays (Supplementary
Figure S2), but not in the presence of DesBP3 and DesBP4
(Supplementary Figure S3), a result likely due to the presence
of the solubilizing DED motif on DesBP3 and DesBP4. The DED
motif generates an electrostatic repulsion with the ED motif on
Aβ42, which is likely to interfere with the designed epitope–
paratope complementarity (Figure 1A). From the analysis of the
normalized curves (Figure 2B), we obtained the dependence of
the half-time of aggregation (t1/2) on the concentrations of the
DesBPs, which indicate that these bicyclic peptides delay the
aggregation process of Aβ42 (Figure 2C).
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FIGURE 1 | Generation of the rationally designed bicyclic peptides. (A) Representation of the six amino acids sequences designed to bind Aβ42 (DesBP1–DesBP6).
Three cysteine residues are included for cyclization (bold) and the binding site obtained from the cascade procedure (green and blue arrows) is inserted between
cysteine residues. Charged residues are added at N- and C-termini to improve solubility and modulate the binding; positive ones (blue) for DesBP1, DesBP2,
DesBP5, and DesBP6, and negative ones (red) for DesBP3 and DesBP4 as controls. Dotted lines mark residues predicted to be involved in backbone–backbone
hydrogen bonding and arrows denote the N- to C-termini direction. (B) Synthesis of the bicyclic peptides. A rationally designed peptide with three cysteine residues
is tethered to the trifunctional compound 1,3,5-tris(bromomethyl)benzene (TBMB) in a nucleophilic substitution reaction.
High Concentrations of DesBPs Delay Aβ42
Aggregation and Decrease ThT Fluorescence
We then tested the effects of high concentrations (0.25- to 16-
fold excess) of the DesBPs on the Aβ42 aggregation process
(Figure 3). The ThT profiles of DesBP1, DesBP2, DesBP5,
and DesBP6 (Figure 3A), but again not of DesBP3 and
DesBP4 (Supplementary Figure S3), showed an increase in
t1/2 (Figure 3B). At the same time, we observed a suppression
of the ThT intensity (Figure 3C) as the concentrations of the
DesBPs were increased. To investigate this phenomenon, we
studied the morphological changes of the aggregates by using
the fluorescent probe ANS, which binds to hydrophobic surfaces.
The comparison of the ThT and ANS profiles is shown in
Figure 3C, and individual ThT and ANS fluorescence profiles at
various concentrations of DesBPs are shown in Supplementary
Figure S4. We observed that the ANS intensity was increased
in a concentration-dependent manner, while the ThT intensity
was suppressed (Figure 3C and Supplementary Figure S4),
indicating that the DesBPs induced structural changes to more
hydrophobic aggregates.
To further characterize the morphology of the aggregates,
we used atomic force microscopy (AFM) after each incubation
in the absence and in the presence of 0.25 and 16 molar
equivalents of the DesBPs (Figure 3D). Representative AFM
images show a morphological transition from fibrillar to
non-fibrillar aggregates, consistent with the increase of ANS
fluorescence. These different morphologies are presumably
caused by the incorporation of the DesBPs into the Aβ42
aggregates. Furthermore, the aggregates did not show seeding
ability, apart from those formed in the presence of DesBP6,
suggesting that they are not fibrillar (Supplementary Figure S5).
Taken together, our results indicate that these DesBPs extend
the lag phase at all concentrations, but appear to exhibit a
concentration-dependent mechanism of modulation of Aβ42
aggregation. At low concentrations, the DesBPs increase the ThT
intensity (Figure 2), while at higher concentrations, they decrease
the ThT intensity by redirecting the aggregation process toward
non-fibrillar aggregates (Figure 3).
Characterization of the Effects of the
DesBPs on the Structures of the
Aggregates of Aβ42
Sub-stoichiometric Concentrations of DesBPs Delay
the Aggregation of Aβ42 Into Fibrillar Structures
To investigate the structures of the Aβ42 aggregates formed in
the presence of the DesBPs, we performed time course DLS
measurements to monitor the early stages of aggregation of
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FIGURE 2 | Kinetic analysis of Aβ42 aggregation in the presence of sub-stoichiometric concentrations of DesBPs. Non-normalized (A) and normalized (B) ThT
fluorescence intensity profiles of Aβ42 aggregation under quiescent conditions at a concentration of 2 µM in the presence of increasing concentrations (0.0–0.9 µM)
of DesBPs (represented by different colors). Representative curves of three replicates are shown. (C) Average half-time (t1/2) of the aggregation reaction at different
[Aβ42]:[DesBP] ratios. All experiments were performed in triplicate. Error bars represent standard deviations. For reference, see Ikenoue et al. (2020).
10 µM Aβ42 in the presence of 0.25 molar equivalents of
DesBP (Figure 4A). The results showed a rapid (within 10 min)
appearance of aggregates of about 1.0 µm in size. The ThT
profiles, however, did not show any increase until at least
30 min (Figure 4B), showing that these early aggregates do
not yet have a fully ordered fibrillar structure. In addition, the
growth in the ANS signal within the initial 30 min suggests
the presence of hydrophobic assemblies (Figure 4B). Next, in
the presence of 0.25 molar equivalents of the DesBPs, the Aβ42
concentration was varied from 2 to 10 µM in the ThT assays.
To confirm that the products were still amyloid fibrils, far-UV
CD spectrometry measurements were performed in the case of
10 µM of Aβ42. After a 1-day incubation, the CD spectra showed
fibrillar structures, although aggregates in the presence of DesBP2
and DesBP5 showed less β-sheet contents (Figure 4E). The ThT
profiles indicate that the aggregation of Aβ42 was enhanced in
the presence of the DesBPs (Figure 4F), without the formation of
significant amounts of off-pathway aggregates (Supplementary
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FIGURE 3 | Kinetic analysis and morphological changes of Aβ42 aggregation in the presence of high concentrations of DesBPs. (A) ThT kinetic profiles of Aβ42
aggregation under quiescent conditions at a concentration of 2 µM in the absence or in the presence of increasing concentrations (0.5–32 µM) of DesBPs
(represented by different colors). Representative profiles of three replicates are shown. (B) Average half-time (t1/2) of the aggregation at each [Aβ42]:[DesBP] ratio.
(C) Averaged maximum ThT (closed circle) and ANS (opened circle) fluorescence intensity at each [Aβ42]:[DesBP] ratio (kinetic profiles are shown in Supplementary
Figure S4). All aggregation experiments were performed in triplicate. (D) Representative AFM images of Aβ42 aggregates at the end of the ThT assay (32 h) formed
in the presence of 0 (left), 0.25 (middle), and 16 (right) molar equivalents of DesBPs. The scale bar on the AFM images indicates 1 µm, and the scale on the right
represents the height.
FIGURE 4 | Comparison of the structural properties of Aβ42 aggregates at low and high DesBP concentrations. Kinetics of 10 µM Aβ42 aggregation observed by
DLS (A,C), ThT and ANS fluorescence (B,D) in the presence of 0.25 and 16 molar equivalents of DesBP2 and DesBP5. Blue, green, and yellow regions in (B) and
(D) represent the condensation, maturation, and fibrillation phases in the aggregation process of Aβ42, respectively. (E) Secondary structure of Aβ42 aggregates in
the presence of 0.25 molar equivalents DesBPs. Far-UV CD spectra of 10 µM Aβ42 aggregates in the absence (gray) and in the presence (red) of DesBPs. (F,G)
Kinetics of Aβ42 aggregation in the presence of 0.25 molar equivalents DesBPs for increasing concentrations of Aβ42 (from 2 to 10 µM). Normalized ThT profiles (F)
(non-normalized ThT profiles are shown in Supplementary Figure S6), and effects of DesBPs on t1/2, the half time of aggregation; the y-axis reports the logarithm
of the ratio of t1/2 in the presence and absence of a DesBP (G). All experiments were performed in triplicate.
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FIGURE 5 | Effects of the DesBPs described in this work on the aggregation
process of Aβ42. Our results show a condensation of mixed Aβ42/DesBP
assemblies in the early phases of the aggregation process. In the late phases,
at low DesBP concentrations, these assemblies are sufficiently dynamic to be
able to convert into fibrillar structures, as is generally the case for Aβ42
aggregation (Michaels et al., 2020), while at high DesBP concentrations, they
become unable to convert, and mature into amorphous aggregates.
Figure S6). We then evaluated the changes the half-time of
aggregation, finding that the t1/2 values in the presence of
DesBP1, DesBP2, DesBP5, and DesBP6 were increased in a
concentration-dependent manner (Figure 4G).
High Concentrations of DesBPs Delay Aβ42
Aggregation and Promote the Formation of
Amorphous Assemblies
In the presence of 16-fold excess DesBP concentration, for 2 µM
Aβ42 concentration, the analysis of DLS (Figure 4C), ThT, and
ANS (Figure 4D) measurements indicated a gradual formation
of amorphous assemblies, presumably of mixed Aβ42/DesBP
composition, since the intensity of the ThT and ANS decreases
by about 20-fold at high DesBP concentration. At high DesBP
concentrations, the aggregates appear to be no longer fibrillar,
as also shown by the AFM images in Figure 3 and the seeding
experiments in Supplementary Figure S5.
Taken together, these results show that DesBPs promote
the condensation of Aβ42 monomers into assemblies formed
by interacting Aβ42 and DesBP molecules in the early stages
of Aβ42 aggregation. The presence of these assemblies delays,
or even blocks, the formation of structured aggregates in the
late stages.
CONCLUSION
We have described the effects on the aggregation process of
Aβ42 of a panel of bicyclic peptides designed to bind different
epitopes along the Aβ42 sequence. Our results show that in
the early phases of aggregation, there is a condensation of
mixed assemblies formed by the Aβ42 and DesBP molecules
(Figure 5). In the late phases, at low DesBP concentrations, these
assemblies tend to convert into fibrillar structures, while at high
DesBP concentrations, they mature into amorphous aggregates
(Figure 5). These results indicate that bicyclic peptides can be




All reagents were purchased from Sigma–Aldrich, excluding
ThT UltraPure Grade (ThT ≥ 95%), which was purchased
from Eurogentec Ltd.
Rational Design of the Bicyclic Peptides
In our rational design strategy, we regard a bicyclic peptide
sequence as formed by four regions, which are separated by the
three cysteine residues required for bicyclization. In this view,
we designed the two central regions to enable the binding to the
target epitope, as depicted in Figure 1B. By contrast, we retained
some motifs (i.e., Ala-Ala at the N-terminus and Gly-Gly at the
C-terminus for DesBP1, DesBP2, DesBP5, and DesBP6) of the
amino acid sequences of the two terminal regions in order to
facilitate the bicyclization reaction. These regions were further
endowed with charged residues to enhance the overall solubility
of the constructs. We set the length of the binding sites to six
or seven residues, following unsuccessful preliminary attempts
to carry out the bicyclization reaction with longer sequences,
or without the Ala-Ala and Gly-Gly motifs at the termini.
The rational designed was performed with the cascade method
(Sormanni et al., 2015a) (Figure 1A). The charged residues at the
termini were chosen using the CamSol intrinsic solubility score
(Sormanni et al., 2015b).
Recombinant Expression of Aβ42
Aβ42 peptides (MDAEFRHDSGY EVHHQKLVFF
AEDVGSNKGA IIGLMVGGVV IA), here called Aβ42, were
obtained as described previously by recombinant expression in
the Escherichia coli BL21 Gold (DE3) strain (Stratagene) (Habchi
et al., 2017). The purification procedure was carried out by
sonication of E. coli cells, dissolution of inclusion bodies in 8 M
urea, ion exchange in batch mode on diethylaminoethyl cellulose
resin, and lyophilization, followed by further purification using
a Superdex 75 HR 26/60 column (GE Healthcare). Eluates
were analyzed using SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) for the presence of protein products. The fractions
containing recombinant Aβ42 were combined, frozen using
liquid nitrogen, and lyophilized again.
Synthesis of the Bicyclic Peptides
The rationally designed linear peptides were purchased from
ChinaPeptides. In order to achieve cyclization, the peptides were
dissolved in the reaction buffer (20 mM NH4HCO3, 5 mM
EDTA, pH 8.0) at 625 µM. One-quarter volume of 5 mM TBMB
in 100% acetonitrile was added to obtain a final concentration
of 500 µM peptide and 1 mM TBMB and incubated for
1 h at 30◦C. The cyclized peptides were purified by reversed-
phase chromatography on a C18 column using H2O/0.08%
trifluoroacetic acid (TFA) and acetonitrile/0.08% TFA as solvents,
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using a GRACE VYDAC C18 (218TP) column 22 × 250 mm. The
correct mass was then validated by analytical LC/MS (Xevo).
ThT and ANS Fluorescence Aggregation
Assay
Solutions of monomeric peptides were prepared by dissolving
the lyophilized Aβ42 peptide in 6 M GuHCl. The designed
bicyclic peptides in their monomeric form were purified from
oligomeric species and salt using a Superdex 75 10/300 GL
column (GE Healthcare) at a flow rate of 0.5 mL/min, followed
by elution in 20 mM sodium phosphate buffer (pH 8) and
addition of 200 µM EDTA. The peptide concentration was
determined from the absorbance of the integrated peak area
using ε280 = 1495l mol−1 cm−1. The designed bicyclic peptides
were dissolved in water and centrifuged at 20◦C for 1 h at
435,000 g before use. The obtained DesAbs in their monomeric
forms were diluted with buffer to the desired concentration and
supplemented with 20 µM ThT and 50 µM ANS from a 1 mM
stock. ANS experiments were carried out as described previously
(Ikenoue et al., 2020). Seeding experiments were performed in the
presence of 10% (v/v) preformed fibrils, as described previously
(Ikenoue et al., 2020). Preformed fibrils were prepared by the
same procedure used with spontaneous fibril formation. All
samples were prepared in low-binding Eppendorf tubes on ice
using careful pipetting to avoid introduction of air bubbles. Each
sample was then pipetted into multiple wells of a 96-well half-
area, low-binding polyethylene glycol coating plate (Corning
3881) with a clear bottom, at 80 µL per well. Assays were initiated
by placing the 96-well plate at 37◦C under quiescent conditions in
a plate reader (Fluostar Optima; BMG Labtech). The fluorescence
was simultaneously measured through the bottom of the plate
with excitation filter at 440 nm for ThT and 380 nm for ANS and
emission filter at 480 nm.
Static and Dynamic Light Scattering
The light scattering measurements were performed on a
Zetasizer Nano S instrument (Malvern Instruments, Malvern,
United Kingdom) in backscattering mode at 173◦. The
instrument was equipped with a light source with a wavelength
of 633 nm and a Peltier temperature controller at 25◦C. Samples
were prepared as described above, and 70 µL of them was
pipetted into disposal plastic micro cuvette.
CD Spectroscopy
Far-UV CD spectra of proteins and peptides in soluble and
insoluble states were measured with a J-820 spectropolarimeter
(Jasco, Japan) using a cell with a light path of 1 mm at each
condition. Individual Aβ42 solutions were prepared at 10 µM
for CD measurements. The CD signals between 195 and 250 nm
were expressed as mean residue ellipticity [θ] (deg cm2 dmol−1).
Temperature regulation was carried out using a PFD-425S
Peltier-unit (Jasco, Japan).
Atomic Force Microscopy
Atomic force microscopy measurements were carried out in
air with the sample deposited on functionalized mica. To
functionalize the surface, after cleaving, the bare mica substrate
was incubated with a 10 µL drop of 0.05% (v/v) APTES [(3-
aminopropyl)triethoxysilane, Fluka] in Milli-Q water for 1 min at
room temperature, rinsed with Milli-Q water, and then dried by
the passage of a gentle flow of gaseous nitrogen. The preparation
of the mica AFM samples was made at room temperature by
deposition of a 10 µL aliquot of 10 µM solution for 5 min. Then
the samples were rinsed with ultrapure water and dried by a
gentle flow of nitrogen.
Atomic force microscopy imaging was carried out in
intermittent contact mode on a JPK Nanowizard II AFM
recorded with AC mode under ambient conditions using an
integral gain of 120 Hz, post-gain of 0.008 Hz, and 0.3 Hz line-
rate for 4 × 4 µm images. Images flattening and statistical analysis
were performed by SPIP (Image metrology) software.
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Supplementary Figure 1 | Solubility of the DesBPs in the absence of Aβ42
before and after incubation. Static (a) and dynamic (b) light scattering of 50 µM
DesBP monomers solved in phosphate buffer at 5◦C. (c) Far-UV CD spectra of
32 µM DesBP monomers. (d) Representative AFM images of 32 µM DesBPs after
1 day incubation at 37◦C. The scale bar on the AFM images indicates 1 µm, and
the scale on the right represents the height.
Supplementary Figure 2 | Seeding experiments of Aβ42 amyloid fibrils at
sub-stoichiometric concentrations of DesBPs. Non-normalized (a) and normalized
ThT kinetic profiles (b) of Aβ42 aggregation under quiescent conditions at a
concentration of 2 µM in the absence or in the presence of various concentrations
(0.1–0.9 µM) of DesBPs (represented by different colors). (c) Maximum ThT
intensity of the aggregation at each [Aβ42]:[DesBP] ratio. All experiments were
performed in triplicate.
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Supplementary Figure 3 | DesBP3 and DesBP4 do not affect significantly Aβ42
aggregation. ThT (a) and ANS (b) kinetic profiles of Aβ42 aggregation under
quiescent conditions at a concentration of 2 µM in the absence or in the presence
of various concentration (0.5–32 µM) of DesBPs (represented by different colors).
(c) Representative AFM images of Aβ42 aggregates in the presence of 16 molar
equivalents of DesBPs. The scale bar on the AFM images indicates 1 µm, and the
scale on the right represents the height. All aggregation experiments were
performed in triplicate.
Supplementary Figure 4 | Kinetic profile of ThT and ANS fluorescence of Aβ42
aggregation at various concentrations of DesBPs. ThT (closed circles) and ANS
(opened circles) kinetic profiles of Aβ42 aggregation under quiescent conditions
at a concentration of 2 µM in the absence or in the presence of various
concentrations (0.5–32 µM) of DesBP1, DesBP2, DesBP5, and DesBP6
(represented by different colors). All experiments were performed in
triplicate.
Supplementary Figure 5 | Seeded aggregation assay of Aβ42 in the presence of
high molar equivalents of DesBPs. The aggregates formed in the presence of the
DesBPs, with the exception of the case of DesBP6, did not show seeding ability,
indicating that they do not have a fibrillar nature. Experiments were
performed in triplicate.
Supplementary Figure 6 | Kinetics of Aβ42 aggregation in the presence of 0.25
molar equivalents DesBPs. We report the results for increasing concentrations of
Aβ42, from 2 to 10 µM. All experiments were performed in triplicate.
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